RT Journal Article SR Electronic T1 Predictors of mortality in cancer patients requiring intensive care support: Two-centered cohort study JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP P1994 VO 40 IS Suppl 56 A1 Dursun Tatar A1 Özlem Yazicioglu Moçin A1 Pinar Cimen A1 Zuhal Karakurt A1 Cenk Kirakli A1 Gökay Güngör A1 Ozlem Ediboglu A1 Nalan Adiguzel A1 Emel Tellioglu A1 Cuneyt Salturk A1 Merih Balci YR 2012 UL http://erj.ersjournals.com/content/40/Suppl_56/P1994.abstract AB Aim: Acute respiratory failure (ARF) can be developed in cancer patients due to disease progression or as a complication of treatment. In our study we aimed to identify the factors associated with mortality in cancer patients admitted to the intensive care unit (ICU) due to ARF.Method: A retrospective-cohort study was planned in two ICUs of training hospital of chest diseases between January 2008 and december 2011 period. Demographic data, type of cancer, cause of ARF, comorbid disease, APACHE II value, type of treatment, and mortality were recorded from the medical records of cancer patients followed in ICU.Results: During the study period 463 (373 male) cancer patients were included in the study followed by two-centers in the ICU. The median age of the patients was 65 (57-72). 78 % of the patients were lung cancer while 22 % of the patients were extrapulmonary cancer and the mortality rates were similar. Cause of ARF in 84 % (n:391) of the patients were due to cancer invasion and 12 % was infections. APACHE II value was 24 (18-30) and and ICU day was 5 (2-10). Application of invasive and noninvasive mechanical ventilation was respectively 20% and 74%. The mortality rate of the cancer patients in ICU was 54 %. APACHE II value was significantly higher in patients who were died (p<0.001). The mortality of the female patients were higher (p<0.05).Conclusion: The mortality is higher than the overall ICU mortality, in patients with advanced cancer who required ICU support. In our study; APACHE II value and female gender are the marker of high mortality in cancer patients developed ARF.